Seika News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Seika. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Seika Today - Breaking & Trending Today

Newron Reports Compelling Additional Data Documenting the Efficacy of Evenamide in Pivotal Study 008A in Poorly Responding Schizophrenia Patients

Newron Reports Compelling Additional Data Documenting the Efficacy of Evenamide in Pivotal Study 008A in Poorly Responding Schizophrenia Patients
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

Kyongsang Bukto , South Korea , United Arab Emirates , United States , United Kingdom , Ravi Anand , Swiss Exchange , Dusseldorf Stock Exchange , Supernus Pharmaceuticals , Newron Pharmaceuticals , European Union , Negative Syndrome Scale , Total Score , Clinical Global Impression , Chief Medical Officer , Latin America , Meiji Seika ,

Newron Announces Positive Top-line Results From Potentially Pivotal Phase II/III Study 008A With Evenamide in Schizophrenia Patients

Ad hoc announcement pursuant to Art. 53 LR

Primary endpoint and key secondary endpoint of study met; drug was well tolerated, with no safety concerns identified

Glutamatergic inhibition mechanism. ....

United States , South Korea , Kyongsang Bukto , United Kingdom , United Arab Emirates , Ravi Anand , European Union , Newron Pharmaceuticals , Dusseldorf Stock Exchange , Swiss Exchange , Supernus Pharmaceuticals , Negative Syndrome Scale , Total Score , Clinical Global Impression , Chief Medical Officer , Conference Call , Latin America , Meiji Seika ,

Data from Newron's study 014/015 and an evenamide clinical development outlook presented at the 2024 Annual Congress of the Schizophrenia International Research Society (SIRS) -April 08, 2024 at 01:02 am EDT

EQS-News: Newron Pharmaceuticals S.p.A.

/ Key word: Study results

Data from Newron’s study 014/015 and an evenamide clinical development outlook presented at the 2024 Annual. ....

Kyongsang Bukto , South Korea , Sri Lanka , United States , United Kingdom , United Arab Emirates , Stefan Weber , Anne Hennecke Caroline Bergmann , Valentin Handschin , Paul Sagan , Schizophrenia International Research Society , European Union , Mc Services , Supernus Pharmaceuticals , Newron Pharmaceuticals , Negative Syndrome Scale , Clinical Global Impression , Strauss Carpenter Level , Latin America , Meiji Seika , Ciara Martin , Natalie Garland Collins , Caroline Bergmann ,

Data from Newron's study 014/015 and an evenamide clinical development outlook presented at the 2024 Annual Congress of the Schizophrenia International Research Society (SIRS) -April 08, 2024 at 07:06 am EDT

Data from study 014/015, a phase II trial evaluating evenamide as add-on therapy for patients with treatment-resistant schizophrenia for up to one year

Presentation of study design for potentially. ....

United Kingdom , Kyongsang Bukto , South Korea , Sri Lanka , United Arab Emirates , United States , Dusseldorf Stock Exchange , Newron Pharmaceuticals , Supernus Pharmaceuticals , Schizophrenia International Research Society , Swiss Exchange , European Union , Negative Syndrome Scale , Clinical Global Impression , Strauss Carpenter Level , Latin America , Meiji Seika ,